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Abstract
Introduction: -synuclein-induced degeneration of dopaminergic neurons has been proposed
to be central to the early progression of Parkinson’s disease. This highlights the need to identify
factors that are neuroprotective or neuroregenerative against -synuclein-induced
degeneration. Due to their potent neurotrophic effects on nigrostriatal dopaminergic neurons,
we hypothesized that members of the bone morphogenetic protein (BMP) family have potential
to protect these cells against -synuclein.
Methods: To identify the most relevant BMP ligands, we used unbiased gene co-expression
analysis to identify all BMP family members having a significant positive correlation with five
markers of dopaminergic neurons in the human substantia nigra (SN).We then tested the ability
of lead BMPs to promote neurite growth in SH-SY5Y cells and in primary cultures of ventral
mesencephalon (VM) dopaminergic neurons, treated with either 6-OHDA or MPP+, or
overexpressing wild-type or A53T -synuclein.
Results: Only the expression of BMP2 was found to be significantly correlated with multiple
dopaminergic markers in the SN. We found that BMP2 treatment promoted neurite growth in
SH-SY5Y cells and in dopaminergic neurons. Moreover, BMP2 treatment promoted neurite
growth in both SH-SY5Y cells and VM neurons, treated with the neurotoxins 6-OHDA or
MPP+. Furthermore, BMP2 promoted neurite growth in cells overexpressing wild-type or
A53T--synuclein.
Conclusion: These findings are important given that clinical trials of two neurotrophic factors,
GDNF and neurturin, have failed to meet their primary endpoints. Our findings are a key first
step in rationalising the further study of BMP2 as a potential neurotrophic factor in synuclein-based translational models of Parkinson’s disease.
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Introduction
The degeneration of midbrain dopaminergic (mDA) neurons leading to the loss of striatal
innervation is central to the progression of Parkinson’s disease (PD) (1). -synuclein has been
linked to PD since a number of mutations, such as the A30P (2) or A53T mutation in SNCA
(3), as well as triplications (4) or duplications (5) of SNCA, are associated with autosomal
dominant PD, while SNCA is also a susceptibility gene for sporadic PD (6). In addition, synuclein is the main component of Lewy bodies and Lewy neurites, which are pathological
hallmarks of PD (7). Overexpression of α-synuclein in individual cultured mDA neurons has
been shown to reduce neurite growth (8). This is also supported by the reduced connectivity
and spine formation (9), and decreased neurite length and axonal degeneration (10), found in
iPSC-derived neurons with SNCA triplication. Moreover iPSC-derived mDA neurons carrying
the A53T mutation also develop neurite degeneration (11). These studies show that -synuclein
can lead to axonal and somal degeneration and highlight the need to identify factors that can
promote mDA neurite growth in neurons carrying an -synuclein load.
Bone morphogenetic proteins (BMPs) are a group of 15 structurally-related proteins
that are members of the transforming growth factor (TGF)- superfamily of ligands (12). The
BMP receptors (BMPRs) (BMPR2 with BMPR1A or BMPR1B) are expressed in embryonic
and adult rat mDA neurons (13). Adult male BMPR2 dominant-negative mice display an
almost complete loss (~90%) of striatal innervation, with reduced locomotor activity (14).
Previous studies have shown that BMP treatment increases mDA neuron number in midbrain
cultures in vitro (15, 16). Additionally, BMP treatment, or overexpression of a constitutivelyactive BMPR1B, promotes neurite growth in SH-SY5Y cells (17), and in primary cultures of
mDA neurons through the canonical Smad signalling pathway (12, 13, 17, 18). Moreover,
knockdown of a negative regulator of BMP-Smad signalling during development promotes
mDA neurite growth and leads to dopaminergic hyperinnervation of the striatum (19).
However, the expression profiles of individual BMPs in mDA neurons are unknown, as is
information on the effects of BMPs on neurite growth in cells overexpressing -synuclein.
Here we show that of all BMPs, only transcripts for BMP2 and the BMPRs are coexpressed with transcripts for multiple markers of mDA neurons in the human SN.
Additionally, we show that BMP2 promotes neurite growth and protects against neurotoxininduced and wild-type- and A53T--synuclein-induced neurite degeneration in SH-SY5Y cells
and in primary cultures of mDA neurons. These findings are an important step in rationalizing
the further study of BMP2 in neurotrophic factor therapy for PD.

Materials and Methods
Gene expression analysis of the human SN
Human SN gene expression data from healthy controls (GSE:60863) (20) and age-matched
control and PD patients (GSE:49036) (21) were analysed separately using the R2: Genomics
Analysis and Visualization Platform (http://r2.amc.nl). Pearson correlation analysis with a false
discovery rate (FDR) multiple testing correction was used to identify all genes that were coexpressed with five dopaminergic neuronal markers: ALDH1A1, NR4A2, KCNJ6, TH and
LMX1B in the SN, and four markers enriched in Purkinje cells in the cerebellum: PDE1A1,
CBLN1, PDE9A, CALB1 (GSE:60863). All gene expression data are presented as log2
expression values. Differences in expression were determined using one-way ANOVA with
post hoc Tukey’s test.

Cell culture
SH-SY5Y cells and embryonic day (E) 14 rat VM were cultured as previously described (13),
under license with full ethical approval. Cultures were treated with 50ng/ml recombinant
human (rh)BMP2 (Gibco), 6-OHDA (0-15µM) (Sigma), or MPP+ (0-1mM) (Sigma), unless
otherwise indicated. For transfection experiments, SH-SY5Y cells and E14 VM cultures were
transfected with 0.5-1µg of plasmid DNA using the TransIT-X2® Dynamic Delivery System
(Mirus Bio) according to the manufacturer’s instructions. SH-SY5Y cells were seeded at a
density of 2.5x104 cells per well and allowed to reach ≥80% confluency prior to transfection.
E14 VM cultures were seeded at a density of 1.5x105 cells per well. The TransIT-X2:DNA
complex was prepared according to the manufacturer’s specifications using serum-free
medium, TransIT-X2 reagent and 0.5-1µg/µl stock of control EGFP plasmid or EGFP-synuclein-Wild Type (WT) or EGFP--synuclein-A53T plasmids. These were a kind gift from
David Rubinsztein (Addgene plasmid #40823) (22). The transfection efficiency for SH-SY5Y
cells and E14 VM cells was 31% and 3%, respectively.

Western Blotting
Western blotting was carried out as previously described (19). Cells were lysed in RIPA buffer
and insoluble debris was removed via centrifugation. 28µg of protein was run on a 12% SDSPAGE gel and transferred onto polyvinyl difluoride (PVDF) membranes. The membranes were
incubated with primary antibodies against α-synuclein (1:5000, Merck Millipore) and GAPDH
(1:1000, SCBT) overnight shaking at 4°C, then washed, incubated with horseradish

peroxidase-labelled anti-mouse IgG (1:5000, Invitrogen), washed and developed using the
Pierce™ ECL kit (Thermo Scientific).

Immunocytochemistry
SH-SY5Y cells were fixed in 4% paraformaldehyde (PFA; Sigma) and E14 VM cultures were
fixed in ice-cold methanol or 4% PFA for 15 min at room temperature (RT). Cells were washed
three times for 5 min per wash in 0.02% TritonX-100 (Sigma) in 10mM phosphate buffered
saline (PBS-T), before being blocked in 5% bovine serum albumin (BSA) in 10mM PBS-T for
1 h at RT, then incubated overnight at 4°C in tyrosine hydroxylase (TH) (1:2000, Merck
Millipore; Catalogue number: 36-008) or α-synuclein (SNCA) (1:2000, Merck Millipore;
Catalogue number: AB152) diluted in 1% BSA in 10mM PBS-T. Following three 5-min
washes in PBS-T, cells were incubated in the appropriate Alexa Fluor 488- or 594- conjugated
secondary antibodies (1:500; Invitrogen) diluted in 1% BSA in 10mM PBS-T, for 2 h.
Following washes in PBS-T, cells were counterstained with DAPI (1:3000; Sigma) and imaged
using an Olympus IX71.

Assessment of cellular morphology
To assess cellular morphology, the lengths of 5 randomly-selected neurites were measured in
no less than 15 randomly-selected fields per N, resulting in at least 225 neurites analysed per
experiment. To assess somal area, the somal sizes of 5 randomly-selected cells were measured
in 15 randomly-selected fields per N, resulting in 225 cells analysed per experiment. To
determine the number of TH positive (TH+) cells, TH and DAPI counts were completed in 15
randomly-selected fields and the numbers of TH+ cells were expressed as percentages of the
total DAPI-stained cells. All experiments were repeated at least 3 times and all analyses were
performed using Image J software.

Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6 (©2018 GraphPad Software, CA
USA). Unpaired student’s t-test or one-way ANOVA with post hoc Dunnett’s or Tukey’s test
were used as indicated to determine significant differences between groups. Results were
deemed to be significant when p < 0.05. All cell data are presented as mean ± SEM.

Results
Co-expression analysis of the human SN identifies an association between BMPs/BMPRs
and markers of mDA neurons.
We first conducted an unbiased co-expression analysis to identify all genes that were coexpressed with five markers of mDA neurons in the human SN: ALDH1A1, NR4A2/Nurr1,
KCNJ6/Girk2, TH and LMX1B (Fig. 1a, b) (20). These analyses revealed significant positive
correlations only for specific ligands and receptors of the BMP subfamily, namely BMP2,
BMPR2, BMPR1A and BMPR1B, from the lists of co-expressed genes (Fig. 1b -f). While all of
the BMPRs were positively correlated with four markers of Purkinje neurons in the human
cerebellum (PDE1A, CBLN1, PDE9A, CALB1), BMP2 was not (Fig. 1g). BMP2 was also
expressed at significantly higher levels in the SN than in the putamen or cerebellum (Fig. 1h).
We next analysed gene expression data from age- and gender-matched samples in GSE:49036
(21) to examine BMP2 and BMPR expression in the SN of patients at distinct stages of PD.
These analyses showed a significant downregulation of BMP2 in the SN of PD patients at Braak
stage 5/6 compared to controls (Fig. 1i), while no significant differences were observed for
BMPR1B (data not shown) or BMPR2 (Fig. 1j). These data suggest that BMP2-BMPR
signalling may play a functional role in mDA neurons in the human SN.

BMP2 promotes neurite growth in 6-OHDA- and MPP+--treated, and WT--synucleinand A53T--synuclein-overexpressing, SH-SY5Y cells.
We next determined that 72h treatment with 1mM MPP+ or 15µM 6-OHDA had a significant
detrimental effect on neurite length in SH-SY5Y cells (Fig. 2a, b). To determine if rhBMP2
treatment could promote neurite growth in cells treated with 6-OHDA or MPP+, SH-SH5Y
cells were treated with 50 ng/ml rhBMP2 and cultured with or without either neurotoxin for
72h. Here, rhBMP2 promoted neurite growth in cells treated with either 6-OHDA or MPP+,
both of which had a detrimental effect on neurite growth in SH-SY5Y cells (Fig. 2c, d). To
investigate if rhBMP2 could promote neurite growth in cells with a PD-causing WT- or A53T-synuclein overload, SH-SH5Y cells were transfected with a control-GFP, a WT-synuclein-GFP or an A53T--synuclein-GFP overexpression plasmid. Western blotting and
immunocytochemistry revealed strong expression of -synuclein in cells transfected with synuclein-GFP (Fig. 2e, f). Quantification of GFP-positive neurites showed that both WT- and
A53T--synuclein overexpression induced decreases in neurite length compared to controls (p

< 0.01) (Fig. 2g, h). However, rhBMP2 treatment was found to promote neurite growth in both
WT- and A53T--synuclein-overexpressing cells (Fig. 2g, h).
rhBMP2 protects cultured midbrain dopaminergic neurons against 6-OHDA and MPP+.
As SH-SY5Y cells are catecholaminergic and do not recapitulate all the features of mDA
neurons, we next examined the effects of rhBMP2 in primary cultures from E14 rat VM. We
first determined that 72h treatment with 5µM MPP+ or 6-OHDA had a significant detrimental
effect on TH+ mDA neurite length (Fig. 3a, b). rhBMP2 treatment induced significant increases
in mDA neurite growth, even in those cultures treated with 6-OHDA or MPP+ (Fig. 3c, d). We
then examined the effect of MPP+ and 6-OHDA on somal area and found a reduction in somal
size which was not seen in cultures treated with rhBMP2 (Fig. 3e). We also assessed cell
viability and found that both neurotoxins caused a significant decrease in the number of TH+
neurons, which was partially rescued by rhBMP2 (Fig 3f, h), while the total cell number
remained unaffected (Fig. 3g), indicating a partial neuroprotective effect of rhBMP2. These
data show that rhBMP2 can promote neurite growth and partially protect primary mDA neurons
against 6-OHDA- and MPP+-induced degeneration.

rhBMP2 promotes neurite growth in WT--synuclein- and A53T--synucleinoverexpressing cultured midbrain dopaminergic neurons.
To investigate if rhBMP2 could also promote neurite growth in mDA neurons overexpressing
WT- or A53T--synuclein, E14 rat VM cultures were transfected with both WT--synucleinGFP and A53T--synuclein-GFP overexpression plasmids, or with a control-GFP plasmid.
Immunocytochemistry (Fig. 4a) and subsequent quantification of -synuclein staining (given
the transfection efficiency was not sufficient for western blotting) showed that E14 VM
cultures transfected with either the WT--synuclein-GFP or A53T--synuclein-GFP plasmid
showed strong expression of -synuclein compared to cells transfected with the control
plasmid (Fig. 4b) . While the overexpression of WT--synuclein-GFP or A53T--synuclein
had no effect on somal area compared to the control-GFP group (Fig. 4c), both WT-synuclein-GFP and A53T--synuclein-GFP resulted in a significant decrease in neurite length
compared to controls (p < 0.001) (Fig. 4d, e). In contrast, WT--synuclein-GFP or A53T-synuclein-GFP expressing cells that were also treated with rhBMP2 were not significantly
different from the controls. These data show that WT- or A53T--synuclein reduced neurite

growth without affecting somal area, and that rhBMP2 can promote neurite growth in cultured
mDA neurons overexpressing WT- or A53T--synuclein.

Discussion
In the present study, we have shown that the expression of BMP2 and its receptors,
BMPR1A, BMPR1B and BMPR2, is positively correlated with five key markers of
dopaminergic function in the human SN, suggesting a functional relationship between the BMP
pathway and mDA neurons. We have also shown that BMP2 is highly expressed in the SN
compared to the putamen or indeed the cerebellum, an area known to be particularly responsive
to BMPs (23). In agreement with this, previous studies have shown the expression of transcripts
for BMP2, BMPR1B and BMPR2 receptors in the rat midbrain from E12, a period where
neurotrophic support is critical, prior to target innervation (13). Furthermore, we have
identified that BMP2 expression is significantly downregulated in the SN in PD patients at
Braak stage 5/6, while there are no significant changes in the expression of its receptors. The
findings of these studies suggest that endogenous BMP signalling, perhaps mediated by BMP2,
may promote mDA neuronal survival and/or maintain mDA axonal integrity in the adult brain.
Using SH-SY5Y cells as an initial cellular model, we examined the functional role of
BMP2 and found that rhBMP2 exerts a concentration-dependent effect on neurite growth (data
not shown). In support of this, a number of previous studies have shown that rhBMP2 can
promote survival and growth in rodent neurons (for review see ref (12)). In addition, we also
found that rhBMP2 promoted neurite growth against the neuritotoxic effects of two wellestablished dopaminergic neurotoxins, MPP+ and 6-OHDA. We then found that the
overexpression of WT- and A53T--synuclein-GFP in SH-SY5Y cells caused a significant
decrease in neurite length, which was not seen when co-treated with rhBMP2. However, while
SH-SY5Y cells are widely-used as an in vitro model of mDA neurons, they are ultimately
catecholaminergic cells and thus do not replicate all of the features of mDA neurons. To address
this, we used primary cultures of E14 rat VM and found that rhBMP2 treatment protected mDA
neurons against MPP+- and 6-OHDA-induced axonal degeneration. Furthermore, we have
shown that MPP+ causes a reduction to cell soma size, and that both MPP+ and 6-OHDA reduce
numbers of TH+ neurons, which is partially protected by rhBMP2. In support of our findings,
rhBMP2-treatment has also been shown to increase the survival of transplanted E14 VM mDA
neurons and to decrease motor deficits, in 6-OHDA-lesioned rat models of PD (24).

Collectively, these data show that rhBMP2 can protect mDA neurons against neurotoxininduced injury and thus may have significant potential as a neurotrophic factor for use in PD
therapy.
While MPP+ and 6-OHDA are very useful neurotoxins for modelling PD, they do not
mimic the α-synuclein accumulation that is central to disease progression (25). We therefore
overexpressed WT- and A53T-α-synuclein in E14 VM cultures and found a decrease in neurite
length, in agreement with a previous study using E14 rat mDA neurons (8). Here, we found
that rhBMP2 could promote neurite growth against this α-synuclein-induced axonal
degeneration. In addition, while both WT- and A53T- α-synuclein had significant effects on
neurite length, neither WT- or A53T-α-synuclein had an effect on somal size, which is in
agreement with a previous study (8). This is significant as it is possible that the degenerative
aetiology of PD may occur at both somal and axon levels (26). Indeed, there have been several
studies describing axonal degeneration using induced pluripotent stem cell (iPSC)-derived
mDA neurons isolated from patients with PD. Specifically, iPSCs derived from PD patients
with SNCA triplications displayed decreased neuronal differentiation, activity and neurite
outgrowth compared to control iPSCs (27), as well as atypical neurite length and axonal
fragmentation (10). Additionally, it has also been shown that PD patient iPSC-derived mDA
neurons display phenotypic characteristics of PD, including Lewy-like neurites comprised of
pathological α-synuclein, protein aggregation, atypical neurite outgrowth, and fragmented
axons containing swollen varicosities of α-synuclein or Tau, and have a reduced capability to
form synapses (11). These data agree with previous in vivo studies showing that transgenic
mice expressing human α-synuclein develop synaptic dysfunction in striatal DA terminals and
display an age-dependent reduction in DA release (28, 29). Therefore, given this mounting
evidence in support of the role of α-synuclein in axonal degeneration in PD, it is important to
identify neurotrophic factors that can protect against α-synuclein-induced axonal degeneration.
In summary, we report that BMP2 is co-expressed with mDA neuronal markers in the human
SN and is downregulated in PD, and that treatment with rhBMP2 can promote mDA neurite
growth and protect against neurotoxin- and α-synuclein-induced degeneration. These findings
are important given that clinical trials of two dopaminergic neurotrophic factors, GDNF and
neurturin, in PD patients have failed to meet their primary endpoints (30). In light of this, the
findings in our study are an important first step in rationalising the further study of rhBMP2 as
a potential neuroprotective therapy using -synuclein-based translational models of PD.
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Figures and Figure Legends

Figure 1: BMP2-BMPRs are co-expressed with mDA neuron markers in the human SN.
(a, b) Pearson correlation analysis showing the r values and false discovery rate (FDR)corrected p-values (in parentheses) from the SN (n=99). (c-f) Graphs showing the correlation
between BMPR2, BMPR1B, BMPR1A, BMP2 and ALDH1A1 expression in the SN. All data
are 2log expression values. (g) Results of the Pearson correlation analysis showing the r values
and FDR-corrected p-values (in parentheses) of the correlation of BMPR2, BMPR1B, BMPR1A
and BMP2 with four Purkinje neuron markers. (h) Box plot showing BMP2 expression in the
human SN (n=99), putamen (n = 121) and cerebellum (n = 121) (*** p < 0.001 and ### p <
0.001 vs. SN). (i, j) 2log expression values of (i) BMP2 and (j) BMPR2 in the SN of PD at
distinct Braak stages of PD, and in age-matched controls (*p < 0.05 vs. Control). (h-i) One-

way ANOVA with post-hoc Tukey’s test. Raw data was obtained from (b - h) GSE:60863 and
(i, j) GSE:49036 and analysed using the R2: Genomics analysis and visualisation platform
(https://hgserver1.amc.nl/cgi-bin/r2/main.cgi).

Figure 2: rhBMP2 promotes neurite growth in MPP+-treated, 6-OHDA-treated and
A53T -synuclein-overexpressing SH-SY5Y cells.
(a, b) Total neurite length of SH-SY5Y cells following 72h treatment with either (a) MPP+ or
(b) 6-OHDA, at the concentrations indicated. (c) Total neurite length and (d) representative
photomicrographs of SH-SY5Y cells treated with 50ng/ml rhBMP2 and cultured with or
without 1mM MPP+ or 15μM 6-OHDA for 72 h. Scale bar = 100μm. (e) Representative images
of SH-SY5Y cells transfected with constructs expressing GFP (Control-GFP) or A53T-synuclein-GFP (-synA53T-GFP) immunocytochemically stained for -synuclein protein at
24h, scale bar = 10μm; quantification of this expression is shown in (f). (g) Total neurite length
and (h) representative images of transfected SH-SY5Y cells expressing either control-GFP, synWT-GFP or -synA53T-GFP and cultured with or without 50ng/ml rhBMP2 for 72h. Scale
bar = 50μm. All data are presented as mean ± SEM from at least three experiments. (* p < 0.05,
p < 0.01, p < 0.001 vs. control or as indicated. One-way ANOVA with Tukey’s (a, b, c, g) or
Dunnett’s (f) post hoc test).

Figure 3: rhBMP2 promotes neurite growth and partially protects against mDA neuron
loss in MPP+-treated and 6-OHDA-treated primary cultures of rat VM.
Total neurite length of DA neurons in E14 VM cultures following 72h treatment with (a) 6OHDA or (b) MPP+, at the concentrations indicated. (c) Total neurite length and (d)
representative photomicrographs of dopaminergic neurons in E14 VM cultures treated with
50ng/ml rhBMP2 and cultured with or without 5µM MPP+ or 5μM 6-OHDA for 72 h. Scale
bar = 50μm. (e) Somal area, (f) TH+ neurons as a percentage of total cells and (g) number of
cells per field of view, in primary cultures of the E14 rat VM treated with 50ng/ml rhBMP2
and cultured with or without 5μM MPP+ or 5μM 6-OHDA for 72h. (h) Representative
photomicrographs of TH/DAPI-stained E14 VM cultures, treated as indicated. Scale bar =
50µm. All data are presented as mean ± SEM from at least three experiments. (* p < 0.05, p <
0.01, p < 0.001 vs. control or as indicated. One-way ANOVA with Tukey’s post hoc test).

Figure 4: rhBMP2 promotes neurite growth in wild-type -synuclein- and A53T synuclein-overexpressing cells in primary cultures of E14 rat VM.
(a) Representative images of primary cultures of E14 rat VM transfected with constructs
expressing GFP (Control-GFP), -synucleinWT-GFP (-synWT-GFP) or -synuclein A53TGFP (-synA53T-GFP), then immunocytochemically stained for -synuclein at 72h. Scale bar
= 10μm. Quantification of (b) -synuclein expression and (c) cell somal area in cultures
transfected with Control-GFP, -synWT-GFP and -synA53T-GFP. (d) Representative
images (Scale bar = 50μm) and (e) quantification of total neurite length of E14 VM cultures
transfected with Control-GFP, -synWT-GFP and -synA53T-GFP and cultured with or
without 50ng/ml rhBMP2 for 72h. All data are presented as mean ± SEM from at least three
experiments. (*** p < 0.001 vs. control or as indicated. One-way ANOVA with Tukey’s post
hoc test).

